Nous rencontrons actuellement des problèmes temporaires. Les données de marché de cette page sont actuellement retardées. Veuillez patienter... Nous réglons ce problème et restaurons vos listes personnalisées.

Marchés français ouverture 1 h 39 min
  • GlobeNewswire

    Net asset value of the EfTEN United Property Fund as of 31.05.2024

    In May the EfTEN United Property Fund distributed almost 260 thousand euros to unit owners. As a result, the net asset value (NAV) of the fund unit fell by 0.9% to EUR 10.61 in May. Excluding the cash distribution, EfTEN United Property Fund NAV would have increased by 0.1%. If the fund's investment in the EfTEN Real Estate Fund AS shares is reflected on the basis of its net value, the NAV of the EfTEN United Property Fund unit would be 10.70 euros. In June, the fund made the first investment of

  • PR Newswire

    Hansa Biopharma: increase in number of shares and votes

    Hansa Biopharma AB, ("Hansa Biopharma" or the "Company") (NASDAQ: HNSA) (STOCKHOLM: HNSA) today announced that Hansa's registered share capital and number of shares and votes have increased through (i) the issue of 2,305,260 new ordinary shares resolved on 12 April 2024 and registered with the Swedish Companies Registration Office during June 2024, whereby the number of votes increased with 2,305,260 and the share capital increased with SEK 2,305,260, and (ii) conversion of all 2,362,445 issued

  • Insider Monkey

    The Most Expensive Men’s Perfume in the World

    In this article, we will talk about the Most Expensive Men’s Perfume in the World. For our detailed discussion, go directly to the 25 Most Expensive Men’s Perfumes in the World. As previously noted in our article “15 Best Everyday Colognes in 2024,” the global perfume market was estimated to be worth $50.85 billion in […]

  • USA TODAY

    OnPolitics: Biden’s debate debacle raises new questions among Democrats about whether he should bow out

    As USA TODAY’s Susan Page wrote, “Sometimes it's hard to call a winner and loser in a debate. Not this time."

  • PR Newswire

    SURVEY SHOWS AUSTRALIANS WANT MORE ANNUAL LEAVE AS THEY HOLD ON TO WHAT THEY HAVE

    A survey of 899 people conducted by insurance provider Budget Direct revealed that more than 60 per cent of Australians did not take their leave last year.

  • Associated Press Finance

    South African researchers test use of nuclear technology to curb rhino poaching

    Researchers in South Africa have injected radioactive material into the horns of 20 rhinos as part of a research project aimed at reducing poaching. The idea is that radiation detectors already in place at national borders would detect the horns and help authorities arrest poachers and traffickers. The research, which has included the participation of veterinarians and nuclear experts, begins with the animal being tranquilized before a hole is drilled into its horn and the nuclear material carefully inserted.

  • GuruFocus.com

    Decoding McCormick & Co Inc (MKC): A Strategic SWOT Insight

    Unveiling the Strengths and Challenges: A Deep Dive into McCormick & Co Inc's SWOT Analysis

  • GuruFocus.com

    Decoding Carnival PLC (CUK): A Strategic SWOT Insight

    Insightful Analysis of Carnival PLC's Strengths, Weaknesses, Opportunities, and Threats

  • Business Wire

    Genoks and Velsera Forge Strategic Partnership to Revolutionize Cancer Diagnostics in Turkey

    LONDON, June 28, 2024--Genoks, a leading Turkish genomics healthcare company, and Velsera, a global healthcare technology company offering a universal software platform to connect clinical care with discovery, have announced a collaboration aimed at advancing cancer diagnostics and treatment in Turkey and nearby regions.

  • PR Newswire

    Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients

    Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced that the Group has completed STP707 Phase I clinical study with strong safety profile and stable disease activity for treatment of pancreatic cancer patients. This is a dose escalation study conducted in 11 oncology clinics in the U.S. The study involved six cohorts,